The utility of ultrafast MRI and conventional DCE-MRI for predicting histologic aggressiveness in patients with breast cancer
View abstract on PubMed
Summary
This summary is machine-generated.Ultrafast dynamic contrast-enhanced MRI (DCE-MRI) effectively predicts breast cancer invasiveness and aggressive subtypes. Key parameters like maximum slope (MS) and area under the curve (AUC) show high reliability for identifying potential histologic upgrades.
Area Of Science
- Radiology
- Oncology
- Medical Imaging
Background
- Accurate prediction of histologic prognostic markers is crucial for tailoring breast cancer management and prognosis.
- Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) offers valuable insights into tumor characteristics.
Purpose Of The Study
- To determine the predictive capabilities of ultrafast and conventional DCE-MRI features for histopathologic prognostic markers in breast cancer.
- To correlate quantitative and qualitative MRI parameters with molecular subtypes and histologic invasiveness.
Main Methods
- Retrospective review of preoperative MRI scans from 158 women with 163 breast cancers.
- Analysis of inter-observer agreement for ultrafast MRI parameters (AUC, MS, ME, slope).
- Correlation of MRI parameters with histopathologic prognostic markers.
Main Results
- Excellent inter-observer agreement was observed for ultrafast MRI parameters.
- Triple-negative breast cancers (TNBC) showed significant associations with rim enhancement and peritumoral edema.
- Invasive cancers were linked to specific MRI features including lesion type-mass, increased delayed washout, angiovolume, ME, slope, MS, and AUC.
- Regression analysis identified MS and delayed washout, or AUC, delayed washout, and lesion-type mass as predictors of histologic invasiveness.
Conclusions
- Conventional and ultrafast DCE-MRI provide valuable information for predicting histologic underestimation and aggressive breast cancer subtypes.
- Maximum slope (MS) and area under the curve (AUC) from ultrafast MRI are reliable imaging markers for predicting the upgrade from ductal carcinoma in situ (DCIS) to invasive cancer.

